文献速递瓣膜病与结构性心脏病

中危主动脉瓣狭窄经导管与外科换瓣10年随机结局

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2026-01-01

PARTNER 2A试验中危重度症状性主动脉瓣狭窄患者随机接受球囊扩张式TAVR(SAPIEN XT)或外科换瓣,10年随访时TAVR全因死亡率86.1%高于外科82.8%(HR 1.13,95%CI 1.02-1.25,P=0.02),差异主要见于经心尖/经主动脉途径;TAVR再干预率6.3%亦高于外科1.6%(P<0.001)。

要点

  • 中危患者10年全因死亡率TAVR高于外科(86.1% vs 82.8%,HR 1.13,P=0.02)。
  • 经股动脉途径两组死亡率相似(83.9% vs 82.1%,P=0.27)。
  • TAVR10年主动脉瓣再干预率高于外科(6.3% vs 1.6%,P<0.001)。

核心结论

  • 中危主动脉瓣狭窄患者使用SAPIEN XT行TAVR较外科换瓣10年生存率更低,差异主要见于经心尖/经主动脉途径队列。
  • TAVR组10年主动脉瓣再干预率显著高于外科组。

研究设计与样本

  • PARTNER 2A随机试验,2011至2013年57个中心纳入外科中危的重度症状性主动脉瓣狭窄患者。
  • 按经股动脉或经胸(经心尖/经主动脉)解剖适合性分层随机,接受球囊扩张式SAPIEN XT的TAVR或外科换瓣。
  • 瓣膜植入人群共1910例,TAVR 974例(经股动脉749/974,76.9%),外科936例;平均年龄81.6岁,女性45.4%,平均STS评分5.8%。
  • 10年结局评估全因死亡、主动脉瓣再干预及核心实验室判读的超声心动图结局;5年时需患者重新知情同意,并实施生命状态核查以提高全因死亡数据完整性。

主要发现

  • 10年时TAVR组974例中881例(90.5%)、外科组936例中838例(89.5%)可获得生命状态。
  • 经生命状态核查后,10年全因死亡率TAVR为86.1%、外科为82.8%(HR 1.13;95%CI 1.02-1.25;P=0.02)。
  • 按入路分层,经股动脉组TAVR与外科全因死亡率相似(83.9% vs 82.1%,P=0.27)。
  • 经心尖/经主动脉组TAVR死亡率高于外科(93.2% vs 85.1%,P<0.01;交互P=0.03)。
  • 10年主动脉瓣再干预累积发生率TAVR为6.3%、外科为1.6%(P<0.001)。

临床怎么用

  • 中危主动脉瓣狭窄选择TAVR时应考虑入路途径,经心尖/经主动脉途径的长期生存劣势需纳入决策。
  • TAVR后需长期监测主动脉瓣再干预风险,10年再干预率高于外科。

局限性

  • 10年超声心动图数据仅来自TAVR 24例和外科35例,样本量有限。
  • 5年时需患者重新知情同意,可能影响长期随访数据完整性。
  • 结果基于球囊扩张式SAPIEN XT系统,不能直接外推至其他瓣膜平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical aortic valve replacement for symptomatic severe aortic stenosis, but long-term, comparative clinical outcomes and echocardiography data are lacking. OBJECTIVES: Our goal was to compare 10-year clinical and echocardiographic outcomes after balloon-expandable TAVR or surgery in intermediate-risk surgical patients in the PARTNER 2A randomized trial. METHODS: Between 2011 and 2013, patients with severe, symptomatic aortic stenosis at intermediate surgical risk were randomized at 57 centers to TAVR with the balloon-expandable SAPIEN XT system (Edwards Lifesciences) or to surgery. Randomization was stratified by anatomical suitability for transfemoral (TF) or transthoracic (transapical/transaortic [TA/TAo]) access. Ten-year outcomes were evaluated in the valve implant population and included all-cause mortality, aortic valve reintervention, and core laboratory-adjudicated echocardiographic outcomes. To obtain 10-year data, patient reconsent at 5 years was required, and vital status sweeps were implemented to improve data completeness for all-cause mortality. RESULTS: Among 1,910 randomized patients who received a valve, 974 underwent TAVR (TF: 749/974 [76.9%]) and 936 had surgery. Mean patient age was 81.6 years, 45.4% were women, and the mean Society of Thoracic Surgeons score was 5.8%. At 10 years, vital status was available for 881 of 974 patients (90.5%) and 838 of 936 patients (89.5%). All-cause 10-year mortality with vital status sweeps was 86.1% after TAVR and 82.8% after surgery (HR: 1.13; 95% CI: 1.02-1.25; P = 0.02). When stratified by access route, rates of all-cause mortality for TAVR and surgery in the TF group were similar (83.9% vs 82.1%, respectively; P = 0.27), whereas mortality was higher for TAVR in the TA/TAo group (93.2% vs 85.1%; P < 0.01; P for interaction = 0.03). Cumulative incidence rates of aortic valve reintervention at 10 years were 6.3% for TAVR and 1.6% for surgery (P < 0.001). Of the 24 TAVR and 35 surgical patients with available echocardiographic data at 10 years, mean gradients were 12.6 mm Hg and 12.7 mm Hg, respectively. CONCLUSIONS: At the 10-year follow-up, TAVR in intermediate-risk patients with the SAPIEN XT prosthesis compared with surgery was associated with lower survival rates, with differences predominantly observed in the TA/TAo access cohort. TAVR with the XT valve was also associated with significantly higher rates of aortic valve reintervention. (PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk [PII A]; NCT01314313).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Thourani VH, von Stein P, Mack MJ, et al. 10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis. J Am Coll Cardiol. 2026. PMID: 42300821. doi:10.1016/j.jacc.2026.03.169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。